Items (Details) (USD $)	3 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Apr. 30, 2014	Jan. 26, 2014	Aug. 22, 2012	Dec. 08, 2011	Aug. 25, 2011
Details
Cash and cash equivalents held in PRC	$ 1,287,005		$ 1,194,668
Cash and cash equivalents held in US	265		895
Allowance for Doubtful Accounts Receivable	1,142,604		1,143,550
Reserve for obsolete or slow-moving inventories	635,118		635,644
Taxes Payable, Current	57,598		69,298
Net loss1	(504,204)	(585,374)
Numerator for basic EPS, loss applicable to common stock holders	(504,204)	(585,374)
Weighted Average Number of Shares Issued, Basic	173,882,803	173,882,803
Weighted Average Number of Shares Outstanding, Diluted	173,882,803	173,882,803
Earnings Per Share, Basic	$ (0.003)	$ (0.003)
Foreign Currency Exchange Rate, Translation	6.16		6.16
Average exchange rates	6.16	6.18
Research and Development Expense	725	57,268
Shipping, Handling and Transportation Costs	82,777	71,697
Purchase price for apartment units held for sale							2,390,325
Payment of purchase price for apartment units held for sale						1,195,162	717,097
Investment in real estate held for resale	1,962,267		1,963,891
Inventory, Raw Materials, Gross	1,469,348		1,548,181
Inventory, Work in Process, Gross	199,141		44,898
Inventory, Finished Goods, Gross	2,446,872		2,295,930
Inventory, Gross	4,115,361		3,889,009
Reserve for obsolete inventory	(635,118)		(635,644)
Inventories, net	3,480,243		3,253,365
Office Equipment	58,216		58,266
Auto and Trucks	928,262		929,042
Machinery and Equipment, Gross	12,011,777		11,987,404
Buildings and Improvements, Gross	10,294,687		10,303,529
Construction in Progress, Gross	1,720,154		1,284,199
Property, Plant and Equipment, Gross	25,013,096		24,562,440
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(10,226,723)		(9,624,082)
Property and equipment, net	14,786,373		14,938,358
Depreciation expense	610,792	450,085
Share issued for acquisition					7,666,666
Value of Shares issued for Acquisition					1,533,333
Cash paid for acquisition					92,541
Amortization of Acquired Intangible Assets	81,294	81,294
Only Sweet name rights and related technologies	587,183		587,183
Distribution agreement and related distribution channels	1,038,691		1,038,691
Finite-Lived Intangible Assets, Gross	1,625,874		1,625,874
Accumulated amortization of Intangible Assets	(623,253)		(541,959)
Finite-Lived Intangible Assets, Net	1,002,621		1,083,915
Land use right, gross	2,579,787		2,581,947
Accumulated amortization of Land Use Rights	(343,721)		(329,672)
LandUseRight	2,236,066		2,252,275
Amortization expense - Land use rights	14,326	14,286
Accounts receivable - related party	880,319		953,400
Revenue from Related Parties	885,608	1,143,311
Due to Pharmaceutical Corporation	183,777		248,873
Due to Qufu Shengwang	197,685		106,308
Prepaid expenses and other current assets	977,776		1,192,649
Prepayments to suppliers	486,812
Employee advances and others	230,968
Prepaid VAT	77,576
Deposits for Land Use Right	182,420
Grant funding received				1,146,921
Short-term Bank Loans and Notes Payable			811,794
Net revenues - Chinese Medicines	522,194	571,560
Net revenues - Chinese medicine - related party	0	0
Net revenues - Chinese medicine - Total	522,194	571,560
Net revenues - Stevioside - third party	2,428,707	1,002,035
Net revenues - Stevioside - related party	885,608	1,143,311
Net revenues - Stevioside - Total	3,314,315	2,145,346
Net revenues - Total segment and consolidated revenues	3,836,509	2,716,906
Interest income - Chinese Medicines	139	144
Interest income - Stevioside	(63,093)	(15,532)
Interest income - Corporate and other	0	0
Interest income - Total segment and consolidated interest expense	(62,954)	(15,388)
Depreciation and amortization - Chinese Medicines	20,608	0
Depreciation and amortization - Stevioside	685,804	545,665
Depreciation and amortization - Corporate and other	0	0
Depreciation and amortization - Total segment and consolidated depreciation and amortization	706,412	545,665
Loss before taxes and noncontrolling interest - Chinese Medicines	24,115	(8,858)
Loss before taxes and noncontrolling interest - Stevioside	(459,138)	(623,506)
Loss before taxes and noncontrolling interest - Corporate and other	(69,181)	46,990
Segment assets- Chinese Medicines	637,914		605,918
Segment assets-Stevioside	14,148,459		14,332,440
Segment assets-Corporate and other	0		0
Segment assets-Total consolidated assets	14,786,373		14,938,358
Investment in real estate held for resale	1,962,267		1,963,891
Deposits in PRC	$ 1,287,005